Neoadjuvant treatment with tyrosine kinase inhibitors in patients with resectable non-small cell lung cancer

Fernando Franco, Mariano Provencio


We have carefully read the article written by Dr. Zhang et al. in which they reported your surgical experience in six patients with resectable epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) after gefitinib as neoadjuvant therapy (1).